Since immunotherapy becomes a promising therapeutic approach in NSCLC, we evaluated PD-L1 expression in pulmonary LELCs (n = 57) using PD-L1 IHC 22C3 pharmDx. Here, CD274 is linked to non-small cell lung carcinoma.